Company news

Arcturus Therapeutics Holdings Inc. news in 2025

Arcturus Therapeutics Holdings Inc.'s news releases, calls and decks from 2025, newest first.

View company

Arcturus Therapeutics to Attend Upcoming Investor Conference

November 23, 2025

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

November 9, 2025

Arcturus Therapeutics to Attend Upcoming Investor Conferences

November 3, 2025

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025

October 27, 2025

Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program

October 21, 2025

Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress

August 10, 2025

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

July 23, 2025

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

June 29, 2025

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency

June 22, 2025

Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

May 11, 2025

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

April 21, 2025

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

April 9, 2025

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

March 5, 2025

Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

March 4, 2025

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

February 23, 2025

European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

February 13, 2025

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

February 13, 2025

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

February 3, 2025

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

January 30, 2025

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

January 29, 2025

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

January 9, 2025

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

January 5, 2025

Calls in 2025

Decks in 2025